Published in Acta Neuropathol Commun on July 09, 2013
Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy. Oncoimmunology (2015) 0.78
Transcriptomics of maternal and fetal membranes can discriminate between gestational-age matched preterm neonates with and without cognitive impairment diagnosed at 18-24 months. PLoS One (2015) 0.78
Disabled homolog 2 controls macrophage phenotypic polarization and adipose tissue inflammation. J Clin Invest (2016) 0.77
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats. Mol Med Rep (2016) 0.75
Endocytosis and Physiology: Insights from Disabled-2 Deficient Mice. Front Cell Dev Biol (2016) 0.75
Matrine Treatment Blocks NogoA-Induced Neural Inhibitory Signaling Pathway in Ongoing Experimental Autoimmune Encephalomyelitis. Mol Neurobiol (2016) 0.75
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
Microglia in health and disease. J Neurosci Res (2005) 2.74
Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J (2002) 2.53
Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol (1993) 2.53
Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol (1995) 2.34
Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic (2001) 2.31
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain (2002) 2.27
Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci (2003) 2.17
The role of nitric oxide in multiple sclerosis. Lancet Neurol (2002) 2.00
Oxidative damage in multiple sclerosis lesions. Brain (2011) 1.95
Mouse disabled (mDab1): a Src binding protein implicated in neuronal development. EMBO J (1997) 1.95
Drosophila abl tyrosine kinase in embryonic CNS axons: a role in axonogenesis is revealed through dosage-sensitive interactions with disabled. Cell (1989) 1.85
Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem (2005) 1.77
Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A (1995) 1.70
Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. EMBO J (2002) 1.66
A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain (1999) 1.63
Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol (2001) 1.58
Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis. Dev Biol (2002) 1.57
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med (2002) 1.57
Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem (1995) 1.52
Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene (1999) 1.46
The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett (2011) 1.39
Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med (2009) 1.34
Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res (2005) 1.32
MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. Neuroimage (2007) 1.20
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis (2008) 1.20
Endocytosis of megalin by visceral endoderm cells requires the Dab2 adaptor protein. J Cell Sci (2005) 1.19
Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide. Brain Res (2006) 1.17
Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia (2005) 1.14
Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol (1998) 1.14
Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J (2002) 1.10
Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuroimmunol (2007) 1.07
Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol (1997) 1.07
Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia (2006) 1.06
Nitric oxide as an activity marker in multiple sclerosis. J Neurol (2003) 1.01
Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery. J Neurosci Res (2007) 1.00
Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol (1998) 0.98
Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J Neurosci Res (2008) 0.96
Retinoids modulate expression of the endocytic partners megalin, cubilin, and disabled-2 and uptake of vitamin D-binding protein in human mammary cells. J Nutr (2008) 0.95
Endogenous transforming growth factor-beta promotes quiescence of primary microglia in vitro. Glia (2012) 0.93
Analysis of a sequenced cDNA library from multiple sclerosis lesions. J Neuroimmunol (1997) 0.86
Overexpression of COUP-TF1 in murine embryonic stem cells reduces retinoic acid-associated growth arrest and increases extraembryonic endoderm gene expression. Differentiation (2008) 0.86
Cutting edge: Dab2 is a FOXP3 target gene required for regulatory T cell function. J Immunol (2009) 0.85
Serum nitric oxide concentrations in patients with multiple sclerosis and patients with epilepsy. J Neural Transm (Vienna) (2011) 0.84
Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism. PLoS One (2012) 0.84
Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. J Neurosci Res (2000) 0.82
Immunohistochemical studies on disabled-2 protein in the spinal cords of rats with experimental autoimmune encephalomyelitis. Brain Res (2011) 0.80
Involvement of Disabled-2 protein in the central nervous system inflammation following experimental cryoinjury of rat brains. Neurosci Lett (2005) 0.80
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol (2007) 8.24
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.27
Axonal mRNA in uninjured and regenerating cortical mammalian axons. J Neurosci (2009) 2.48
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell (2013) 2.22
The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: the Ausimmune study. Mult Scler (2013) 1.99
Fingolimod after natalizumab and the risk of short-term relapse. Neurology (2014) 1.96
Reduced Treg frequency in LFA-1-deficient mice allows enhanced T effector differentiation and pathology in EAE. Eur J Immunol (2010) 1.58
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med (2002) 1.57
Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. J Clin Neurosci (2007) 1.53
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol (2012) 1.53
Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem (2007) 1.47
MYRF is a membrane-associated transcription factor that autoproteolytically cleaves to directly activate myelin genes. PLoS Biol (2013) 1.45
The exercise-induced expression of BDNF within the hippocampus varies across life-span. Neurobiol Aging (2005) 1.44
Remyelination in multiple sclerosis. J Neurol Sci (2003) 1.43
A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. PLoS One (2010) 1.38
Vitamin D status: multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. J Steroid Biochem Mol Biol (2013) 1.33
The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS One (2008) 1.29
Brain-derived neurotrophic factor promotes central nervous system myelination via a direct effect upon oligodendrocytes. Neurosignals (2011) 1.28
The timecourse of induction of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus following voluntary exercise. Neurosci Lett (2004) 1.28
Comprehensive characterization and failure modes of tungsten microwire arrays in chronic neural implants. J Neural Eng (2012) 1.27
Statin therapy inhibits remyelination in the central nervous system. Am J Pathol (2009) 1.23
Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. Neuroimage (2009) 1.22
Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis. Am J Hum Genet (2002) 1.21
MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. Neuroimage (2007) 1.20
Spatial and temporal gene expression profiling of the contused rat spinal cord. Exp Neurol (2004) 1.20
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model. J Magn Reson Imaging (2008) 1.20
Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage. J Neurosci Res (2010) 1.16
Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. J Acquir Immune Defic Syndr (2010) 1.15
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination. J Neurosci (2008) 1.15
Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem (2009) 1.13
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol (2012) 1.13
Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS. J Neurosci (2012) 1.12
Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One (2012) 1.12
Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim Biophys Acta (2010) 1.11
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination. J Neurosci (2012) 1.11
The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J Neurotrauma (2008) 1.11
Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem (2011) 1.10
Extracellular signal-regulated kinase 1/2 signaling promotes oligodendrocyte myelination in vitro. J Neurochem (2012) 1.09
Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. Proc Natl Acad Sci U S A (2006) 1.06
Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia (2006) 1.06
Modulation of bone morphogenic protein signalling alters numbers of astrocytes and oligodendroglia in the subventricular zone during cuprizone-induced demyelination. J Neurochem (2010) 1.04
A pilot study of novel biomarkers in neonates with hypoxic-ischemic encephalopathy. Pediatr Res (2010) 1.04
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol (2015) 1.04
Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2012) 1.04
Ethanol effects on neonatal rat cortex: comparative analyses of neurotrophic factors, apoptosis-related proteins, and oxidative processes during vulnerable and resistant periods. Brain Res Dev Brain Res (2003) 1.04
Phosphorylated neurofilament heavy chain is a marker of neurodegeneration in Leber hereditary optic neuropathy (LHON). Mol Vis (2008) 1.03
Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions. J Neurosci (2011) 1.03
Detection of phosphorylated NF-H in the cerebrospinal fluid and blood of aneurysmal subarachnoid hemorrhage patients. J Cereb Blood Flow Metab (2008) 1.03
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One (2012) 1.02
Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia (2008) 1.01
Oligodendroglial expression of TrkB independently regulates myelination and progenitor cell proliferation. J Neurosci (2013) 1.01
Immunostaining evidence for PI(4,5)P2 localization at the leading edge of chemoattractant-stimulated HL-60 cells. J Leukoc Biol (2008) 1.01
Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal blood-brain barrier function after traumatic brain injury. J Neurotrauma (2011) 0.98
Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther (2010) 0.98
In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. Neurobiol Dis (2009) 0.98
Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. PLoS One (2013) 0.97
Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res (2004) 0.97
BDNF exerts contrasting effects on peripheral myelination of NGF-dependent and BDNF-dependent DRG neurons. J Neurosci (2009) 0.97
The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. Pediatr Allergy Immunol (2010) 0.97
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J Neurosci Res (2008) 0.96
Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods (2006) 0.95
Diffusion tensor imaging of the optic radiations after optic neuritis. Hum Brain Mapp (2011) 0.95
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J Neurosci (2011) 0.95
A neurotoxic peripherin splice variant in a mouse model of ALS. J Cell Biol (2003) 0.95
Microstructural abnormalities in the trigeminal nerves of patients with trigeminal neuralgia revealed by multiple diffusion metrics. Eur J Radiol (2012) 0.95
The role of neurotrophic factors, apoptosis-related proteins, and endogenous antioxidants in the differential temporal vulnerability of neonatal cerebellum to ethanol. Alcohol Clin Exp Res (2003) 0.94
Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord (2007) 0.94
Effect of bax deletion on ethanol sensitivity in the neonatal rat cerebellum. J Neurobiol (2006) 0.94
The role of neurotrophins in the regulation of myelin development. Neurosignals (2009) 0.94
Separate proteolipid protein/DM20 enhancers serve different lineages and stages of development. J Neurosci (2008) 0.93
A role for galanin in human and experimental inflammatory demyelination. Proc Natl Acad Sci U S A (2009) 0.93
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions. Brain Res (2013) 0.93
Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol (2012) 0.92
MARCKS is a natively unfolded protein with an inaccessible actin-binding site: evidence for long-range intramolecular interactions. J Biol Chem (2005) 0.92
Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. J Neurosci Res (2004) 0.92
Deficiency of XIAP leads to sensitization for Chlamydophila pneumoniae pulmonary infection and dysregulation of innate immune response in mice. J Biol Chem (2010) 0.92
Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. Neuromolecular Med (2010) 0.92
Oligodendrocyte injury in multiple sclerosis: a role for p53. J Neurochem (2003) 0.92
Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol (2014) 0.91
Multiple sclerosis - remyelination failure as a cause of disease progression. Histol Histopathol (2012) 0.91
Extending the clinicopathological spectrum of neurofilament inclusion disease. Acta Neuropathol (2005) 0.91